Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
CC transcript
AGENUS INC (AGEN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/23/2023 8-K Cost Associated with Exit or Disposal Activities, Financial Statements and Exhibits  Interactive Data
Docs: "Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers"
08/08/2023 8-K Quarterly results
Docs: "Agenus Reports Second Quarter 2023 Results"
05/09/2023 8-K Quarterly results
Docs: "Agenus Provides Corporate Update and First Quarter 2023 Financial Results"
04/24/2023 8-K Quarterly results
03/30/2023 8-K Quarterly results
03/14/2023 8-K Quarterly results
Docs: "Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives Botensilimab plus balstilimab showed overall response rates of 23% in microsatellite stable colorectal cancer , 50% in PD-1 refractory non-small cell lung cancer and in seven additional metastatic, late-line cancers in a total of more than 300 patients Randomized Phase 2 trials in MSS CRC, melanoma, and pancreatic cancers are underway; a confirmatory phase 3 trial in MSS CRC is expected to be launched in 2023 Data demonstrating clinical benefit in MSS CRC, NSCLC, ovarian cancer, and sarcomas were presented in plenary sessions at ESMO GI, SITC, and CTOS in 2022, and in a late-breaking oral session at ASCO GI in January 2023 Existing corporate collaborations have potential to generate up to $2.7B ..."
12/23/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/02/2022 8-K Quarterly results
11/08/2022 8-K Quarterly results
Docs: "Agenus Provides Corporate Update and Third Quarter 2022 Financial Report"
08/09/2022 8-K Quarterly results
08/05/2022 8-K Quarterly results
06/14/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
03/25/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Sixth Amended and Restated By-Laws of Agenus Inc",
"Sixth Amended and Restated By-Laws of Agenus Inc"
03/01/2022 8-K Quarterly results
01/06/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
11/09/2021 8-K Quarterly results
Docs: "Agenus Corporate Update and Third Quarter 2021 Financial Report Clinical results presented at SITC show that AGEN1181, as a monotherapy and in combination with balstilimab, shows durable responses in 9 cancer types, including patients whose cancers have recurred following PD-1 therapy Agenus will commence Phase 2/3 trials of AGEN1181 and balstilimab in colorectal and several gynecological cancers Agenus’ cell therapy affiliate, MiNK Therapeutics , launched as a publicly traded company with >$40 million raised to accelerate clinical development AGEN1777, an Fc-enhanced TIGIT bispecific antibody, entered Phase 1 development, triggering a $20M milestone payment from Bristol Myers Squibb After successfully achieving clinical milestones and passing FDA inspections, Agenus withdrew its BLA for b..."
10/22/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Agenus Provides Update on Balstilimab Development"
08/09/2021 8-K Quarterly results
07/26/2021 8-K Quarterly results
06/16/2021 8-K Quarterly results
05/18/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
04/06/2021 8-K Quarterly results
03/15/2021 8-K Quarterly results
01/14/2021 8-K Quarterly results
11/25/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Office Lease by and between Bay Center Investor LLC and Agenus Inc.",
"Office Lease by and between Bay Center Investor LLC and Agenus Inc."
10/29/2020 8-K Quarterly results
Docs: "Agenus R&D Update & Third Quarter Financial Report Balstilimab rolling BLA filing and FDA review underway COVID-19 trial open with patients in screening for iNKT Cell Therapy New data and clinical responses with AGEN1181 to be presented at SITC on NOV11 LEXINGTON, Mass., Oct. 29, 2020 -- Agenus Inc. , an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate and optimize immune response to cancers and infections, today provided a corporate update and reported financial results for the third quarter of 2020. Balstilimab BLA filing initiated and FDA review is underway; data presented at ESMO Balstilimab monotherapy trial achieves response rates of 19% in PD-L1 positive tumors and 14% in PD-L1 positive and nega..."
10/13/2020 8-K Quarterly results
08/31/2020 8-K Quarterly results
08/10/2020 8-K Quarterly results
07/28/2020 8-K Quarterly results
06/22/2020 8-K Quarterly results
06/22/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy